Author of

• 10801

  +

  P1.11 - Poster Session 1 - NSCLC Novel Therapies (ID 208)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10815

    +

    P1.11-014 - Outcome of Metastatic NSCLC patients treated at Windsor Regional Hospital Cancer Program Over 7 years (ID 1290)

    09:30 - 09:30  |  Author(s): M. El Masri
    • Abstract

    Background
    BACKGROUND: Lung cancer is second most commonly diagnosed cancer in Canada and commonest cause of cancer related mortality in men and women. It is estimated that it represents 14% of all new cancer diagnoses in 2013. More than half of the patients are diagnosed when they have metastaic disesse. We wanted to study the survival of metastaic non small cell lung cancer patients treated before and after 2005.

    Methods
    PURPOSE AND METHOD: The purpose of this study was to explore the outcome of metastatic non small cell lung cancer (NSCLC) patients treated at Windsor Regional Hospital Cancer pogram over 7 years. We were specially interested in exploring the influence that advances in systemic management of NSCLC may have had on outcome, in this patient population. A retrospective chart review was conducted on patiets treated from 2003-2009 at Windsor Regional Hospital Cancer Program.Total 483 patients with lung cancer were identified and details of demographics, type of lung cancer, stage, comorbidities and treatment related information was obtained.

    Results
    RESULT: Total 213 patients with metastatic NSCLC were identified. Mean age at diagnosis was 65.55 ± 10.52 years. 54 % were males. While 93.4 % self identified as smokers 76.5 % were heavy smokers. Most common sites of metastatic disease include brain (23%), bones (21.6%), lung (12.7%) and liver (6.6%). While 31.5 % received first line platinum based chemotherapy only 13.6 % received second line teratment. Median survival was 22 weeks. No difference in survival was found between the two groups of patients treated before or after 2005.

    Conclusion
    CONCLUSION: Our findings showed that there was no difference in survival between the two groups of patients who were treated before or after 2005. Median survival was noted to be 22 weeks and we speculate this might be related to patients presenting late in the course of disease and therefore had poor performance status and were unable to receieve the second and third line of treatment. Smoking is associated with poor survival and a large number of patients were smokers in this cohort. This was a single institution retrospective study with small number of patients and we may need larger number to assess the difference in survival. Paradigm in treatment of lung cancer is still shifting and may be we need to wait further to observe any meaningful difference in outcome.